Verve Therapeutics, Inc. announced a private placement to issue common stock to new investor, Eli Lilly and Company for the gross proceeds of $35 million on November 28, 2023. Such lesser amount such that Lilly?s beneficial ownership does not exceed 4.9% of the number of shares of common stock to be outstanding immediately following the closing of the transaction. The shares will be sold to Lilly at a price per share equal to the public offering price.

The proposed concurrent private placement is subject to market and other conditions, and there can be no assurance as to whether or when concurrent private placement may be completed, or as to the actual size or terms of the concurrent private placement.